Rhesus/Cynomolgus IFN-Alpha 2
Recombinant Rhesus/Cynomolgus Interferon Alpha 2 expressed in E.coli
$345.00
Product Info
Bioactivity Measured using cytopathic effect inhibition assays on Bovine (MDBK) cells with VSV and Human (A549) cells with EMCV
The EC50 for bovine IFN is ~ 5 U/ml
The EC50 for human IFN is ~ 1 U/ml.
Specifications
Formulation | Supplied frozen with a carrier protein |
---|---|
Molecular Weight | 19.5 kDa |
Source | cDNA expressed in E.coli |
Purity | > 98% by SDS-PAGE stained by Coomassie Blue Endotoxin level < 1 EU/μg |
Storage | For retention of full activity store at -70°C or below and avoid repeated freeze/thaw cycles |
Accession Number | XM_001107516 |
Tech Info & Data
Background
The cDNA for Rheus/Cynomolgus IFN-Alpha 2 was cloned from the Rhesus cell line LLC-MK2. This was found to be identical to the putative Rhesus IFN-Alpha 2 (XM_001107516) identified as part of the Rhesus genome project. There are 14 AA differences in the mature protein (2 in the signal peptide) between the Rhesus and Human Alpha A (2a) sequence. There are 13 AA differences in the mature protein (2 in the signal peptide) between the Rhesus and Human Alpha 2 (2b) sequence. This is in accord with a previous report [Villinger et al. (1995) J. Immunol. 155:3946] stating that there are 15-16 amino acids different between the Rhesus IFN-Alpha 2 and human alpha 2 (2b) and human alpha A(2a) respectively.
This Rhesus (Macaca mulatta) sequence is also identical to a Cynomolgus (Macaca fascicularis) IFN-Alpha 2 cloned from cDNA isolated from primary hepatocytes (PBL unpublished observation).
Citations
3 Citations
- Mudd, Joseph, et al. (2018). Hallmarks of Primate Lentiviral Immunodeficiency Infection Recapitulate Loss of Innate Lymphoid Cells. Nature Communications, 12 pgs. PMID: 30262807. (link)
- Wonderlich, Elizabeth, et al. (2015). Macrophages and Myeloid Dendritic Cells Lose T Cell-Stimulating Function in Simian Immunodeficiency Virus Infection Associated with Diminished IL-12 and IFN-alpha Production. Journal of Immunology, 9 pgs. PMID: 26297760. (link)
- Dudek, Arkadiusz, et al. (2007). First in Human Phase I Trial of 852A, a Novel Systemic Toll-like Receptor 7 Agonist, to Activate Innate Immune Responses in Patients with Advanced Cancer. Clinical Cancer Research, 8 pgs. PMID: 18056192. (link)
References
- Villinger et al. (1995) J. Immunol. 155:3946.